MORRISVILLE, N.C.--(BUSINESS WIRE)--TearScience®, Inc., a privately-held medical device company, today announced that its system for evaporative dry eye, which includes the LipiView® Ocular Surface Interferometer and LipiFlow® Thermal Pulsation System, increased in acceptance among eye care physicians as a new standard of care in dry eye this month. Unsolicited demand for more than 30 live, in-booth LipiFlow® treatments was met above the seven demonstrations originally scheduled for the ASCRS•ASOA held in Chicago from April 20-24, 2012. Added requests for personal experience with the LipiFlow® treatment was a clear indicator of the impact that the TearScience® commercial offering made when unveiled for the first time since the U.S. Food and Drug Administration’s clearance for treatment of Meibomian gland dysfunction (MGD) and evaporative dry eye.
